CARsgen, Huadong Reach Deal to Commercialize CT053 in China
Huadong Medicine has been granted the exclusive rights in China to commercialize CT053, CARsgen Therapeutics’ investigational cell therapy for people with relapsed or…
Huadong Medicine has been granted the exclusive rights in China to commercialize CT053, CARsgen Therapeutics’ investigational cell therapy for people with relapsed or…